Class A
Ranitidine Hydrochloride Tablets Instructions
Please read the instructions carefully and use as directed or buy and use under the guidance of a pharmacist.
Drug Name
Generic Name: Ranitidine Hydrochloride Tablets
English name: Ranitidine Hydrochloride Tablets
Hanyu Pinyin: Yansuan Leinitiding Pian
Ingredients
This product contains 0.15g of Ranitidine per tablet. Excipients: microcrystalline cellulose, magnesium stearate, stomach-soluble film-coated premix.
Properties]
This product is film-coated tablets, after removing the coating appears off-white to slightly yellow.
【Activity Category
This product is an antacid non-prescription drugs. Indications
It is used to relieve stomach pain, heartburn (heartburn) and acid reflux caused by excessive stomach acid. Specification】0.15g (by ranitidine) 【Dosage】.
Take orally. Adults take 1 tablet once, 2 times a day. Take in the early morning and at bedtime.
[Adverse Reactions].
The following events have been reported in clinical trials or routine treatment with ranitidine, many of which have not been clearly correlated with ranitidine Headache (sometimes severe) may be associated with ranitidine.
CNS: Rare discomfort, dizziness, drowsiness, insomnia and vertigo. Rare reversible confusion, agitation, depression, and hallucinations, mainly in severely ill elderly patients. Rarely reversible blurred vision suggesting changes in regulatory function. Rarely reversible involuntary movement disorders.
Cardiovascular: As with other H2 receptor antagonists, rare tachycardia, bradycardia, atrioventricular block, premature ventricular contractions.
Gastrointestinal: constipation, diarrhea, nausea/vomiting, abdominal discomfort/abdominal pain, rare pancreatitis.
Liver: occasional reports of hepatocellular, cholestatic or mixed hepatitis with or without jaundice. In such cases, ranitidine should be discontinued immediately. These events are generally reversible, but death has rarely occurred. Hepatic failure is rare.
Musculoskeletal: Rarely arthralgia and myalgia.
Hematologic: A few patients present with altered blood counts (leukopenia, granulocytopenia, and thrombocytopenia), which are generally reversible. Rarely granulocyte deficiency, allohemocytopenia, sometimes with myelodysplasia and aplastic anemia, and very rarely acquired immune hemolytic anemia.
Endocrine system: Controlled trials in animals and humans have not shown that ranitidine stimulates pituitary hormones or has anti-androgenic activity. When ranitidine was used as a substitute for cimetidine, gynecomastia and impotence caused by cimetidine in hypersecretory patients subsided. However, impotence and hypogonadism have occasionally been reported in male patients taking ranitidine, and their incidence is similar to that of the normal population. Breast discharge and gynecomastia have been reported rarely in both men and women.
Skin: Rash, including rare erythema multiforme. Rare alopecia and vasculitis.
Respiratory: A large epidemiologic study showed an increased risk of pneumonia in patients who were using H2 receptor antagonists compared to those who discontinued treatment with H2 receptor antagonists. However, the causal relationship between H2 receptor antagonists and pneumonia is not clear.
Other: Rare hypersensitivity reactions (e.g., bronchospasm, fever, rash, eosinophilia), allergic reactions, angioneurotic edema, acute interstitial nephritis, and mild elevation of serum creatinine.
Contraindications】 1. Contraindicated in children under 8 years of age. 2. 2. Contraindicated in pregnant and lactating women. 3.
3. Contraindicated in patients with hypersensitivity to the product and its ingredients. If symptoms are not relieved, please consult your physician or pharmacist. 2. 2. Use with caution in elderly patients and patients with hepatic or renal insufficiency. 3. 3. If overdose or serious adverse reactions occur, seek medical attention immediately. 4. Consult a physician or pharmacist for dosage for children over 8 years of age. 5. This product is contraindicated for allergic persons and should be used with caution for allergic persons. 6. Do not use if there is any change in the properties of this product. 7. Keep this product out of the reach of children. 8. 8. Children must be used under adult supervision. 9. If you are using other drugs, consult your physician or pharmacist before using this product.
10. Avoid use in patients with a history of acute porphyria.
Drug Interaction】 1. The clearance of procainamide may be reduced when used with procainamide. 2. Drug interactions may occur if used with other drugs, please consult your physician or pharmacist for details.
3. Alterations in prothrombin time have been reported when used in combination with warfarin.
Ranitidine affects the pH in the stomach, which may lead to increased absorption (e.g., triazolam, midazolam, glipizide) or decreased absorption (e.g., ketoconazole, atazanavir, dilaudid, gefitinib).
Pharmacological effects】It is an H2 receptor inhibitor, which has the effect of inhibiting gastric acid secretion. It is rapidly absorbed through the gastrointestinal tract after oral administration. Storage】Store in a dry place under shade and seal.
Package】Packaged in high-density polyethylene bottle for oral solid medicine, 30 tablets/bottle.
Expiration date】12 months
Execution Standard
Approval Number】State Drug Administration H37022067
[Instruction Revision Date
【Manufacturer】 Company name: Ruiyang Pharmaceutical Co.
Address: No. 1, Ruiyang Road, Yiyuan County, Shandong Province
Postal Code: 256100
Telephone number: 4006 123458; 15853312365
Fax number: 0533-3248777
Web address: http://www.reyoung.com
Mailbox: [email protected]
If you have any questions, please contact with the manufacturer